RECIST 1.1-Update and clarification: From the RECIST committee

Lawrence H Schwartz; Saskia Litière; Elisabeth de Vries; Robert Ford; Stephen Gwyther; Sumithra Mandrekar; Lalitha Shankar; Jan Bogaerts; Alice Chen; Janet Dancey; Wendy Hayes; F Stephen Hodi; Otto S Hoekstra; Erich P Huang; Nancy Lin; Yan Liu; Patrick Therasse; Jedd D Wolchok; Lesley Seymour

doi:10.1016/j.ejca.2016.03.081

RECIST 1.1-Update and clarification: From the RECIST committee

Eur J Cancer. 2016 Jul:62:132-7. doi: 10.1016/j.ejca.2016.03.081. Epub 2016 May 14.

Authors

Lawrence H Schwartz¹, Saskia Litière², Elisabeth de Vries³, Robert Ford⁴, Stephen Gwyther⁵, Sumithra Mandrekar⁶, Lalitha Shankar⁷, Jan Bogaerts², Alice Chen⁸, Janet Dancey⁹, Wendy Hayes¹⁰, F Stephen Hodi¹¹, Otto S Hoekstra¹², Erich P Huang¹³, Nancy Lin¹¹, Yan Liu², Patrick Therasse¹⁴, Jedd D Wolchok¹⁵, Lesley Seymour⁹

Affiliations

¹ Department of Radiology, Columbia University Medical Center, New York, NY, USA; New York Presbyterian Hospital, New York, NY, USA. Electronic address: LSchwartz@columbia.edu.
² EORTC HQ, Brussels, Belgium.
³ Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands.
⁴ Clinical Trials Imaging Consulting, NJ, USA.
⁵ Department of Medical Imaging, East Surrey Hospital, Redhill, Surrey, UK.
⁶ Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
⁷ Clinical Trials Branch, Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
⁸ Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
⁹ Canadian Cancer Trials Group, Queen's University, Kingston, Canada.
¹⁰ Exploratory Clinical & Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA.
¹¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
¹² Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
¹³ National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
¹⁴ Laboratoires Servier, Paris, France.
¹⁵ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical and Graduate Colleges, New York, NY, USA; Ludwig Institute for Cancer Research, New York, NY, USA.

Abstract

The Response Evaluation Criteria in Solid Tumours (RECIST) were developed and published in 2000, based on the original World Health Organisation guidelines first published in 1981. In 2009, revisions were made (RECIST 1.1) incorporating major changes, including a reduction in the number of lesions to be assessed, a new measurement method to classify lymph nodes as pathologic or normal, the clarification of the requirement to confirm a complete response or partial response and new methodologies for more appropriate measurement of disease progression. The purpose of this paper was to summarise the questions posed and the clarifications provided as an update to the 2009 publication.

Keywords: Clarifications; RECIST; Tumour response.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Advisory Committees
Disease Progression
Humans
Lymph Nodes / pathology
Neoplasms / diagnostic imaging
Neoplasms / pathology
Neoplasms / therapy*
Response Evaluation Criteria in Solid Tumors*
Tomography, X-Ray Computed
Treatment Outcome

Abstract

Publication types

MeSH terms

Grants and funding